The post Oracle and Ci4CC Collaborate to Enhance AI in Cancer Research appeared on BitcoinEthereumNews.com. Rongchai Wang Nov 07, 2025 11:54 Oracle Health and Ci4CC are collaborating to advance AI-driven oncology care and research, aiming to integrate clinical and genomic data for personalized medicine solutions. Oracle Health and Life Sciences has announced a strategic partnership with the Cancer Center Informatics Society (Ci4CC), a nonprofit organization that brings together cancer centers, researchers, and industry innovators. This collaboration is aimed at accelerating artificial intelligence (AI) innovation in oncology care and research, according to Oracle. Advancing Oncology Care The partnership will leverage Oracle’s advanced technological capabilities alongside Ci4CC’s Initiatives Program and its expansive network of National Cancer Institute (NCI)-Designated and Community Care Cancer Centers. Together, the organizations aim to design an electronic health record (EHR) system optimized specifically for cancer care. Seema Verma, Executive Vice President and General Manager of Oracle Health and Life Sciences, emphasized the importance of AI and data science in combating cancer, a leading cause of death worldwide. Verma noted that by combining Ci4CC’s expertise and network with Oracle’s AI-powered healthcare solutions, the collaboration could significantly accelerate discoveries that may contribute to curing cancer. Innovative Approaches in Clinical Research The collaboration seeks to foster initiatives across various facets of oncology care and clinical research. This includes the integration of clinical and genomic data to create personalized medicine solutions, development of AI-driven approaches for clinical trial innovation and drug development, and the establishment of comprehensive real-world evidence frameworks aimed at advancing precision oncology platforms. Sorena Nadaf-Rahrov, President & CEO of the Cancer Center Informatics Society, regards the alliance with Oracle as a pivotal moment for Ci4CC. Nadaf-Rahrov highlighted that advancements in cancer research and clinical care are best achieved through collaborative networks, which are central to Ci4CC’s mission. Data-Driven Health Innovations By integrating Oracle’s state-of-the-art AI technology… The post Oracle and Ci4CC Collaborate to Enhance AI in Cancer Research appeared on BitcoinEthereumNews.com. Rongchai Wang Nov 07, 2025 11:54 Oracle Health and Ci4CC are collaborating to advance AI-driven oncology care and research, aiming to integrate clinical and genomic data for personalized medicine solutions. Oracle Health and Life Sciences has announced a strategic partnership with the Cancer Center Informatics Society (Ci4CC), a nonprofit organization that brings together cancer centers, researchers, and industry innovators. This collaboration is aimed at accelerating artificial intelligence (AI) innovation in oncology care and research, according to Oracle. Advancing Oncology Care The partnership will leverage Oracle’s advanced technological capabilities alongside Ci4CC’s Initiatives Program and its expansive network of National Cancer Institute (NCI)-Designated and Community Care Cancer Centers. Together, the organizations aim to design an electronic health record (EHR) system optimized specifically for cancer care. Seema Verma, Executive Vice President and General Manager of Oracle Health and Life Sciences, emphasized the importance of AI and data science in combating cancer, a leading cause of death worldwide. Verma noted that by combining Ci4CC’s expertise and network with Oracle’s AI-powered healthcare solutions, the collaboration could significantly accelerate discoveries that may contribute to curing cancer. Innovative Approaches in Clinical Research The collaboration seeks to foster initiatives across various facets of oncology care and clinical research. This includes the integration of clinical and genomic data to create personalized medicine solutions, development of AI-driven approaches for clinical trial innovation and drug development, and the establishment of comprehensive real-world evidence frameworks aimed at advancing precision oncology platforms. Sorena Nadaf-Rahrov, President & CEO of the Cancer Center Informatics Society, regards the alliance with Oracle as a pivotal moment for Ci4CC. Nadaf-Rahrov highlighted that advancements in cancer research and clinical care are best achieved through collaborative networks, which are central to Ci4CC’s mission. Data-Driven Health Innovations By integrating Oracle’s state-of-the-art AI technology…

Oracle and Ci4CC Collaborate to Enhance AI in Cancer Research

2 min read


Rongchai Wang
Nov 07, 2025 11:54

Oracle Health and Ci4CC are collaborating to advance AI-driven oncology care and research, aiming to integrate clinical and genomic data for personalized medicine solutions.

Oracle Health and Life Sciences has announced a strategic partnership with the Cancer Center Informatics Society (Ci4CC), a nonprofit organization that brings together cancer centers, researchers, and industry innovators. This collaboration is aimed at accelerating artificial intelligence (AI) innovation in oncology care and research, according to Oracle.

Advancing Oncology Care

The partnership will leverage Oracle’s advanced technological capabilities alongside Ci4CC’s Initiatives Program and its expansive network of National Cancer Institute (NCI)-Designated and Community Care Cancer Centers. Together, the organizations aim to design an electronic health record (EHR) system optimized specifically for cancer care.

Seema Verma, Executive Vice President and General Manager of Oracle Health and Life Sciences, emphasized the importance of AI and data science in combating cancer, a leading cause of death worldwide. Verma noted that by combining Ci4CC’s expertise and network with Oracle’s AI-powered healthcare solutions, the collaboration could significantly accelerate discoveries that may contribute to curing cancer.

Innovative Approaches in Clinical Research

The collaboration seeks to foster initiatives across various facets of oncology care and clinical research. This includes the integration of clinical and genomic data to create personalized medicine solutions, development of AI-driven approaches for clinical trial innovation and drug development, and the establishment of comprehensive real-world evidence frameworks aimed at advancing precision oncology platforms.

Sorena Nadaf-Rahrov, President & CEO of the Cancer Center Informatics Society, regards the alliance with Oracle as a pivotal moment for Ci4CC. Nadaf-Rahrov highlighted that advancements in cancer research and clinical care are best achieved through collaborative networks, which are central to Ci4CC’s mission.

Data-Driven Health Innovations

By integrating Oracle’s state-of-the-art AI technology with real-world data from Ci4CC’s network of cancer centers, the collaboration aims to transform data into actionable knowledge that can redefine cancer research and improve patient care. This strategic partnership is part of a non-binding agreement, indicating a flexible yet committed approach to achieving their shared objectives.

Image source: Shutterstock

Source: https://blockchain.news/news/oracle-ci4cc-collaborate-enhance-ai-cancer-research

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Strategy to initiate a bitcoin security program addressing quantum uncertainty

Strategy to initiate a bitcoin security program addressing quantum uncertainty

Markets Share Share this article
Copy linkX (Twitter)LinkedInFacebookEmail
Strategy to initiate a bitcoin security prog
Share
Coindesk2026/02/06 18:21
Strategic Shift Impacts Crypto Trading Landscape

Strategic Shift Impacts Crypto Trading Landscape

The post Strategic Shift Impacts Crypto Trading Landscape appeared on BitcoinEthereumNews.com. Bybit Delists MILK: Strategic Shift Impacts Crypto Trading Landscape
Share
BitcoinEthereumNews2026/02/06 18:01
SEC clears framework for fast-tracked crypto ETF listings

SEC clears framework for fast-tracked crypto ETF listings

The post SEC clears framework for fast-tracked crypto ETF listings appeared on BitcoinEthereumNews.com. The Securities and Exchange Commission has approved new generic listing standards for spot crypto exchange-traded funds, clearing the way for faster approvals. Summary SEC has greenlighted new generic listing standards for spot crypto ETFs. Rule change eliminates lengthy case-by-case approvals, aligning crypto ETFs with commodity funds. Grayscale’s Digital Large Cap Fund and Bitcoin ETF options also gain approval. The U.S. SEC has approved new generic listing standards that will allow exchanges to fast-track spot crypto ETFs, marking a pivotal shift in U.S. digital asset regulation. According to a Sept. 17 press release, the SEC voted to approve rule changes from Nasdaq, NYSE Arca, and Cboe BZX, enabling them to list and trade commodity-based trust shares, including those holding spot digital assets, without submitting individual proposals for each product. A streamlined path for crypto ETFs Under the new rules, an ETF can be listed without SEC sign-off if its underlying asset trades on a market with surveillance-sharing agreements, has active CFTC-regulated futures contracts for at least six months, or already represents at least 40% of an existing listed ETF. This brings crypto ETFs in line with traditional commodity-based funds under Rule 6c-11, eliminating a process that could take up to 240 days. SEC chair Paul Atkins said the move was designed to “maximize investor choice and foster innovation” while ensuring the U.S. remains the leading market for digital assets. Jamie Selway, director of the division of trading and markets, called the framework “a rational, rules-based approach” that balances access with investor protection. First products already approved Alongside the new standards, the SEC cleared the listing of the Grayscale Digital Large Cap Fund, which tracks spot assets based on the CoinDesk 5 Index. It also approved trading of options tied to the Cboe Bitcoin U.S. ETF Index and its mini version, with…
Share
BitcoinEthereumNews2025/09/18 14:04